Will targeting oropharyngeal gonorrhoea delay the further emergence of drug-resistant Neisseria gonorrhoeae strains?

Sexually Transmitted Infections

Volumn 91, Issue 4, 2015, Pages 234-237

  Lewis, D A ^a,b  

^a WESTERN SYDNEY SEXUAL HEALTH CENTRE   (Australia)

^b University of Sydney   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; QUINOLONE DERIVATIVE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIUM CULTURE; BACTERIUM DETECTION; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CROSS REACTION; DISEASE CONTROL; DNA TRANSFER; DRUG EFFICACY; DRUG TARGETING; DRUG TREATMENT FAILURE; GONORRHEA; GROWTH INHIBITION; HIGH RISK POPULATION; HUMAN; INCIDENCE; INFECTION RISK; LIFE THREAT; MEN WHO HAVE SEX WITH MEN; NEISSERIA GONORRHOEAE; NUCLEIC ACID AMPLIFICATION; OROPHARYNGEAL GONORRHOEA; OROPHARYNX; PATHOGENESIS; PHARYNX DISEASE; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW (TOPIC); BACTERIAL GENE; DRUG EFFECTS; FEMALE; GENOTYPE; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOUTH MUCOSA; MUCOSITIS; PATHOGENICITY; PHARYNGITIS; SEXUAL BEHAVIOR;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; FEMALE; FLUOROQUINOLONES; GENES, BACTERIAL; GENOTYPE; GONORRHEA; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MOUTH MUCOSA; MUCOSITIS; NEISSERIA GONORRHOEAE; NUCLEIC ACID AMPLIFICATION TECHNIQUES; PHARYNGITIS; PREVALENCE; PUBLIC HEALTH; SEXUAL BEHAVIOR;

EID: 84930592840     PISSN: 13684973     EISSN: 14723263     Source Type: Journal    
DOI: 10.1136/sextrans-2014-051731     Document Type: Review

References (42)

1. Cohen MS. Sexually transmitted diseases enhance HIV transmission: No longer a hypothesis. Lancet 1998;351(Suppl 3):5-7.
2. Lewis DA. Global resistance of Neisseria gonorrhoeae: When theory becomes reality. Curr Opin Infect Dis 2014;27:62-7.
3. Tapsall JW, Ndowa F, Lewis DA, et al. Meeting the public health challenge of multidrug-and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther 2009;7:821-34.
4. Bolan GA, Sparling PF, Wasserheit JN. The emerging threat of untreatable gonococcal infection. N Engl J Med 2012;366:485-7.
5. Lewis DA. The role of core groups in the emergence and dissemination of antimicrobial-resistant N gonorrhoeae. Sex Transm Infect 2013;89(Suppl 4):iv47-51.
6. Lewis DA. Gonorrhoea resistance among men-who-have-sex-with-men: What's oral sex got to do with it? S Afr J Epid Infect 2013;28:77.
7. Ito M, Deguchi T, Mizutani KS, et al. Emergence and spread of Neisseria gonorrhoeae clinical isolates harboring mosaic-like structure of penicillin-binding protein 2 in Central Japan. Antimicrob Agents Chemother 2005;49:137-43.
8. Ameyama S, Onodera S, Takahata M, et al. Mosaic-like structure of penicillin-binding protein 2 gene (penA) in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime. Antimicrob Agents Chemother 2002;46:3744-9.
9. Osaka K, Takakura T, Narukawa K, et al. Analysis of amino acid sequences of penicillin-binding protein 2 in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime and ceftriaxone. J Infect Chemother 2008;14:195-203.
10. Wallin J, Siegel MS. Pharyngeal Neisseria gonorrhoeae: Coloniser or pathogen? Br Med J 1979;1:1462-3.
11. Hutt DM, Judson FN. Epidemiology and treatment of oropharyngeal gonorrhea. Ann Intern Med 1986;104:655-8.
12. Willmott FE. Transfer of gonococcal pharyngitis by kissing? Br J Vener Dis 1974;50:317-18.
13. World Health Organization. Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus. Geneva: WHO, 2013.
14. Mitchell M, Rane V, Fairley CK, et al. Sampling technique is important for optimal isolation of pharyngeal gonorrhoea. Sex Transm Infect 2013;89:557-60.
15. Page-Shafer K, Graves A, Kent C, et al. Increased sensitivity of DNA amplification testing for the detection of pharyngeal gonorrhea in men who have sex with men. Clin Infect Dis 2002;34:173-6.
16. Schachter J, Moncada J, Liska S, et al. Nucleic acid amplification tests in the diagnosis of chlamydial and gonococcal infections of the oropharynx and rectum in men who have sex with men. Sex Transm Dis 2008;35:637-42.
17. Whiley DM, Tapsall JW, Sloots TP. Nucleic acid amplification testing for Neisseria gonorrhoeae: An ongoing challenge. J Mol Diagn 2006;8:3-15.
18. Marcus U, Bremer V, Hamouda O, et al. Understanding recent increases in the incidence of sexually transmitted infections in men having sex with men: Changes in risk behavior from risk avoidance to risk reduction. Sex Transm Dis 2006;33:11-17.
19. Lister NA, Smith A, Tabrizi S, et al. Screening for Neisseria gonorrhoeae and Chlamydia trachomatis in men who have sex with men at male-only saunas. Sex Transm Dis 2003;30:886-9.
20. Morris SR, Klausner JD, Buchbinder SP, et al. Prevalence and incidence of pharyngeal gonorrhea in a longitudinal sample of men who have sex with men: The EXPLORE study. Clin Infect Dis 2006;43:1284-9.
21. Centers for Disease Control and Prevention. Men who have sex with men. Sexually Transmitted Diseases Surveillance. 2006. http://www.cdc.gov/std/stats06/msm.htm (accessed 22 Mar 2015).
22. Dilley JW, Loeb L, Casey S, et al. Treating asymptomatic sexually transmitted diseases at anonymous HIV counseling and testing sites. Sex Transm Dis 2003;30:874-5.
23. Malhotra-Kumar S, Lammens C, Coenen S, et al. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: A randomised, double-blind, placebo-controlled study. Lancet 2007;369:482-90.
24. Jonsson M, Qvarnstrom Y, Engstrand L, et al. Clarithromycin treatment selects for persistent macrolide-resistant bacteria in throat commensal flora. Int J Antimicrob Agents 2005;25:68-74.
25. Wiesner PJ, Tronca E, Bonin P, et al. Clinical spectrum of pharyngeal gonococcal infection. N Engl J Med 1973;288:181-5.
26. Evans CM, Pratt CB, Matheson M, et al. Nasopharyngeal colonization by Neisseria lactamica and induction of protective immunity against Neisseria meningitidis. Clin Infect Dis 2011;52:70-7.
27. Qvarnstrom Y, Swedberg G. Sulphonamide resistant commensal Neisseria with alterations in the dihydropteroate synthase can be isolated from carriers not exposed to sulphonamides. BMC Microbiol 2002;2:34.
28. Hamilton HL, Dominguez NM, Schwartz KJ, et al. Neisseria gonorrhoeae secretes chromosomal DNA via a novel type IV secretion system. Mol Microbiol 2005;55:1704-21.
29. Goodman SD, Scocca JJ. Identification and arrangement of the DNA sequence recognized in specific transformation of Neisseria gonorrhoeae. Proc Natl Acad Sci USA 1988;85:6982-6.
30. Morse SA, Lysko PG, McFarland L, et al. Gonococcal strains from homosexual men have outer membranes with reduced permeability to hydrophobic molecules. Infect Immun 1982;37:432-8.
31. Moran JS. Treating uncomplicated Neisseria gonorrhoeae infections: Is the anatomic site of infection important? Sex Transm Dis 1995;22:39-47.
32. Judson FN, Ehret JM, Root CJ. Comparative study of ceftriaxone and aqueous procaine penicillin G in the treatment of uncomplicated gonorrhea in women. Antimicrob Agents Chemother 1983;23:218-20.
33. Lafferty WE, Hughes JP, Handsfield HH. Sexually transmitted diseases in men who have sex with men. Acquisition of gonorrhea and nongonococcal urethritis by fellatio and implications for STD/HIV prevention. Sex Transm Dis 1997;24: 272-8.
34. Manavi K, Young H, McMillan A. The outcome of oropharyngeal gonorrhoea treatment with different regimens. Int J STD AIDS 2005;16:68-70.
35. Tapsall J, Read P, Carmody C, et al. Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods. J Med Microbiol 2009;58:683-7.
36. Piercy EA, Bawdon RE, Mackowiak PA. Penetration of ciprofloxacin into saliva and nasal secretions and effect of the drug on the oropharyngeal flora of ill subjects. Antimicrob Agents Chemother 1989;33:1645-6.
37. Bergan T, Delin C, Johansen S, et al. Pharmacokinetics of ciprofloxacin and effect of repeated dosage on salivary and fecal microflora. Antimicrob Agents Chemother 1986;29:298-302.
38. Najjar TA, Alkharfy KM, Saad SY. Mechanism and implication of cephalosporin penetration into oropharyngeal mucosa. J Infect Chemother 2009;15:70-4.
39. Deguchi T, Yasuda M, Yokoi S, et al. Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval. J Infect Chemother 2003;9:35-9.
40. STI in Gay Men Action Group. Australian sexually transmitted infection and HIV testing guidelines 2014 [cited 22 March 2015]. http://stipu.nsw.gov.au/wp-content/uploads/STIGMA-Testing-Guidelines-Final-v5.pdf
41. Magooa MP, Muller EE, Gumede L, et al. Determination of Neisseria gonorrhoeae susceptibility to ciprofloxacin in clinical specimens from men using a real-time PCR assay. Int J Antimicrob Agents 2013;42:63-7.
42. Buono SA, Watson TD, Borenstein LA, et al. Stemming the tide of drug-resistant Neisseria gonorrhoeae: The need for an individualized approach to treatment. J Antimicrob Chemother 2015;70:374-81.